The combination of Cagrilintide 5mg and Semaglutide 5mg refers to a high-dose pairing of two metabolic-regulating peptides currently under development for obesity and type 2 diabetes. This dual-mechanism therapy is primarily known by the investigational brand name CagriSema.

Core Mechanisms

This combination uses a synergistic approach to suppress appetite through two distinct pathways:

Semaglutide (GLP-1 Receptor Agonist): Mimics the glucagon-like peptide-1 hormone to slow gastric emptying, stimulate insulin, and signal fullness to the brain.
Cagrilintide (Long-acting Amylin Analogue): Mimics amylin, a pancreatic hormone co-secreted with insulin that enhances satiety and further delays stomach emptying.

Clinical Efficacy (2025/2026 Data)

As of early 2026, clinical trial results have demonstrated significant outcomes:

Weight Loss: In Phase III trials (REDEFINE 1), participants without diabetes achieved an average of 20% to 23% body weight reduction over 68 weeks.
Diabetes Management: For those with type 2 diabetes, the combination showed weight loss of approximately 16% and substantial improvements in HbA1c levels compared to either drug alone.
Cardiovascular Benefits: Studies noted improvements in blood pressure, lipid levels, and waist circumference

Dosage and Status

Official Maintenance Dose: In official clinical trials (CagriSema), the target maintenance dose is typically 2.4mg of each component once weekly.
Research Peptides: The “5mg + 5mg” configuration is frequently found in the research peptide market (often as lyophilized powder for reconstitution) but is not currently a standard FDA-approved medical prescription dose.
Availability: Novo Nordisk is expected to submit CagriSema for FDA approval in early 2026, potentially making it commercially available by late 2026.